Fuan Pharmaceutical Co., Ltd. won the production approval as soon as the end of the year

In the early stage of the market for the above-mentioned drugs, the person said that the two products have good therapeutic effect and are irreplaceable, with sales of more than $1 billion in the global market The two products of the company have a first mover advantage in China, and the company has made various preparations for the sales of these two heavyweight products It is estimated that the sales of these two products will reach tens of millions next year, The sales volume will exceed 300 million yuan in the next few years The main products of Fu'an pharmaceutical industry are antibiotics, among which the raw materials and preparations of aztreonam are the main sources of income and profit at present Due to the limited anti hypertensive effect, the company's performance has declined In order to change the situation of single original products, the company has been actively transforming to specialized drugs since 2012 Heavy weight generic drugs such as tovaptan, which is used to treat heart failure and cirrhosis, and Nabil hydrochloride, which is used to treat mild to moderate essential hypertension, are expected by the company.